Protecting Consumer Access to Generic Drugs Act of 2026
Summary
The Protecting Consumer Access to Generic Drugs Act of 2026 (HR10887) was introduced in the House on October 22, 2026, and referred to the Energy and Commerce and Judiciary Committees. The bill aims to enhance consumer access to generic drugs by targeting anti-competitive practices, but it is in early legislative stages with no cosponsors, making near-term passage unlikely.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR10887 is an early-stage bill with no cosponsors, reducing its likelihood of passage in the 119th Congress.
- 2.If passed, the bill would benefit generic drug manufacturers by reducing anti-competitive barriers.
- 3.No immediate market impact is expected due to the bill's procedural status and limited legislative momentum.
Market Implications
The bill, if enacted, would structurally benefit generic drug manufacturers like $TEVA, $VTRS, $AMRX, and $PRGO by accelerating market entry and reducing litigation costs. Brand-name pharmaceutical companies could face increased competition, but the impact is uncertain and distant. Given the early legislative stage and absence of cosponsors, the bill is unlikely to advance in the current Congress, limiting near-term market implications.
Full Analysis
The Protecting Consumer Access to Generic Drugs Act of 2026 (HR10887) was introduced by Rep. Magaziner (D-RI) on October 22, 2026, and referred to two committees. The bill's title suggests it addresses barriers to generic drug entry, such as pay-for-delay settlements or REMS abuse, which would benefit generic manufacturers. However, the bill is in an early stage with no cosponsors, indicating limited legislative momentum. No funding is authorized, as the bill likely focuses on regulatory changes rather than appropriations. There are no related presidential actions or converging signals directly tied to this legislation. If enacted, generic drug companies like Teva ($TEVA), Viatris ($VTRS), Amneal ($AMRX), and Perrigo ($PRGO) would be structural winners due to reduced barriers to market entry. Brand-name pharmaceutical companies with large patent portfolios could face increased competition, but the bill's early stage and lack of momentum suggest no immediate market impact. The legislative path requires committee markups, floor votes, and Senate consideration, which is unlikely in the current session given the late date and lack of support.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Restricts anti-competitive practices that delay generic drug entry, such as reverse payment settlements and REMS abuse.
Who must act
Brand-name drug manufacturers and generic companies that engage in settlement agreements that delay generic competition.
What happens
Reduced ability for brand companies to delay generic entry, leading to faster FDA approval and market launch of generic alternatives.
Stock impact
Teva, as one of the largest generic drug manufacturers, would benefit from a more level playing field, potentially increasing its pipeline of new generic launches and reducing litigation costs.
What the bill does
Restricts anti-competitive practices that delay generic drug entry, such as reverse payment settlements and REMS abuse.
Who must act
Brand-name drug manufacturers and generic companies that engage in settlement agreements that delay generic competition.
What happens
Reduced ability for brand companies to delay generic entry, leading to faster FDA approval and market launch of generic alternatives.
Stock impact
Viatris, with a significant generic drug portfolio, would benefit from reduced barriers to market entry, potentially accelerating revenue from new product launches.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend subsection (q) of section 505 of the Federal Food, Drug, and Cosmetic Act to clarify the process for denying certain petitions whose primary purpose is to delay the approval of an application submitted under subsection (b)(2) or (j) of such section 505, and for other purposes.
To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Skinny Labels, Big Savings Act
Skinny Labels, Big Savings Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Advancing Women's Health to Improve Outcomes in All Phases of Life
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Enhancing Program Integrity and Integrity and Interagency Coordination in the Administration of the H-1B Nonimmigrant Visa Program
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
Accelerating Access To Veterans' Benefits And Employment Opportunities
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →